|Articles|June 4, 2013

MorphoSys and GlaxoSmithKline Partner in Antibody Pact

Author(s)BioPharm International Editors

MorphoSys has formeda global agreement with GlaxoSmithKline (GSK) to develop and commercialize MOR103, MorphoSys's proprietary HuCAL-derived antibody for treating mild to moderate rheumatoid arthritis. Under the agreement, GSK assumes responsibility for all subsequent development and commercialization of MOR103. MorphoSys receives an immediate upfront payment of EUR 22.5 million ($29.4 million) and up to EUR 423 million ($552 million), in addition to tiered, double-digit royalties on net sales, based on achieving certain developmental, regulatory, commercial and sales-based milestones.

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

3D illustration of three golden spherical nanoparticles, one shown in cross-section to reveal a layered lipid shell, with a blue helical nucleic acid strand winding around them against a black background. | Image Credit: © Love Employee - stock.adobe.com

October 2nd, 2026

Novartis Licenses Abogen's mRNA-Encoded CD19xCD3 T-Cell Engager ABO2203 for Autoimmune Diseases

Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.

Three injection pens labeled Wegovy, Ozempic, and Victoza crossed behind a bottle of Wegovy semaglutide 1.5 mg tablets on a white background. | Image Credit: © silukstockimages - stock.adobe.com

September 29th, 2026

Novo Nordisk Licenses Hengrui's Once-Weekly Oral GLP-1/GIP Dual Agonist HRS-1596 in Deal Worth Up to $2.6 Billion

Novo gains global rights, excluding Greater China, to HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist that Hengrui says has potential for once-weekly oral dosing in obesity and type 2 diabetes.

October 2nd, 2026

The BioPharm Brief: Room Temperature, RNA, and ADCs

CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.

Close-up of an older person's hands, with the thumb of one hand pressing into the palm of the other, against a blurred teal background. | Image Credit: © eyepark - stock.adobe.com

October 2nd, 2026

Artiva to Present AlloNK Data Showing CAR T-Like B-Cell Depletion in Rheumatologic Diseases at ACR 2026

Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.

Tablet, science team and people learning for cancer cure, help or medical development in laboratory. Training, investigation or research info with scientists in clinical trial for medicine internship | Image credit: © CoetzeeRising/peopleimages.com - © CoetzeeRising/peopleimages.com - stock.adobe.com

October 2nd, 2026

CaseBioscience Joins $7.3 Million ARPA-H Team on Cell Preservation

The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.

antibody-drug conjugation modality impacts overall therapeutic efficacy in brain tumors 3d rendering | Image credit: © Love Employee - © Love Employee - stock.adobe.com

October 2nd, 2026

AstraZeneca, Daiichi Sankyo, and Summit to Combine Datroway, Ivonescimab

A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.

October 1st, 2026

Former FDA Oncology Reviewer Paz Vellanki on Novel Endpoints and Early FDA Engagement Under CDER's ARC Program

Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.

3D illustration of a single-stranded RNA molecule with nucleotide bases extending from a twisting backbone, shown in purple, pink, and yellow against a black background. | Image Credit: © Dr_Microbe - stock.adobe.com

October 1st, 2026

Wave Life Sciences Aligns With FDA on Registrational Path for RNA Editing Therapy WVE-006 in AATD

Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.